Mark Alvino Sells 2,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 2,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $6.38, for a total transaction of $12,760.00. Following the transaction, the director now directly owns 90,435 shares of the company's stock, valued at approximately $576,975.30. This trade represents a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Mark Alvino also recently made the following trade(s):

• On Friday, May 16th, Mark Alvino sold 8,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.68, for a total transaction of $45,440.00.

Abeona Therapeutics Price Performance

ABEO stock traded down $0.02 during midday trading on Friday, reaching $6.14. The company had a trading volume of 946,742 shares, compared to its average volume of 630,613. The company has a market capitalization of $314.10 million, a price-to-earnings ratio of -2.28 and a beta of 1.68. The stock has a 50 day moving average price of $5.40 and a 200-day moving average price of $5.56. Abeona Therapeutics Inc has a 1-year low of $3.93 and a 1-year high of $7.32. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.11. Equities research analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ABEO shares. Stifel Nicolaus reduced their target price on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price for the company. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. HC Wainwright boosted their target price on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $18.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Adage Capital Partners GP L.L.C. raised its stake in Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Western Standard LLC raised its stake in Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Jane Street Group LLC raised its stake in Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock worth $732,000 after acquiring an additional 118,262 shares in the last quarter. 683 Capital Management LLC raised its stake in Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock worth $4,411,000 after acquiring an additional 116,845 shares in the last quarter. Finally, Newtyn Management LLC raised its stake in Abeona Therapeutics by 26.3% during the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after acquiring an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.